Floatz logo

Daunorubicin

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome

National Cancer Institute (NCI)Phase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BB
Decitabine
National Cancer Institute (NCI)
Phase 3BB
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
Cediranib
University of Southern California
Phase 3BB
Cyclophosphamide
City of Hope Medical Center
Phase 3BB

View all 28 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →